Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited (RGC) Stock Overview
Explore Regencell Bioscience Holdings Limited’s financial performance, market position, analyst ratings, and future outlook.
RGC Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Regencell Bioscience Holdings Limited (RGC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $3.23.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -4682.18 and a market capitalization of 8.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Mr. Yat-Gai Au
12
First Commercial Building, Causeway Bay
2021